Fluorine labelling of therapeutic human tolerogenic dendritic cells for (19)F-magnetic resonance imaging

Tolerogenic dendritic cell (tolDC) therapies aim to restore self-tolerance in patients suffering from autoimmune diseases. Phase 1 clinical trials with tolDC have shown the feasibility and safety of this approach, but have also highlighted a lack of understanding of their distribution in vivo. Fluor...

Descripción completa

Detalles Bibliográficos
Autores principales: Cooke, Fiona, Neal, Mary, Wood, Matthew J., de Vries, I. Jolanda M., Anderson, Amy E., Diboll, Julie, Pratt, Arthur G., Stanway, James, Nicorescu, Ioana, Moyse, Nicholas, Hiles, Dawn, Caulfield, David, Dickinson, Anne M., Blamire, Andrew M., Thelwall, Pete, Isaacs, John D., Hilkens, Catharien M. U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574244/
https://www.ncbi.nlm.nih.gov/pubmed/36263039
http://dx.doi.org/10.3389/fimmu.2022.988667

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574244/
https://www.ncbi.nlm.nih.gov/pubmed/36263039
http://dx.doi.org/10.3389/fimmu.2022.988667

Ejemplares similares